臨床研究等提出・公開システム

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for DLBCL. (SOUNDTRACK-B)

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma

Hibi Kazushige

Astrazeneka K.K

3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka

RD-clinical-information-Japan@astrazeneca.com

Hibi Kazushige

Astrazeneka K.K

3-1, Ofuka-cho, Kita-ku, Osaka-shi, Osaka

+81-6-4802-3533

RD-clinical-information-Japan@astrazeneca.com

Recruiting

Oct. 01, 2024

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

- Aged 18 to 80 years old

- Histologically confirmed relapsed refractory FL (Module 1) and DLBCL (Module 2) after at least 2 prior lines of therapy

- ECOG performance status 0 to 2

- Locally confirmed CD-19 expression in lymphoma cells after progression from last CD 19 directed therapy

- FDG-avid disease with at least one bi-dimensionally measurable nodal lesion (defined as > 1.5 cm in its longest dimension), or extranodal lesion (defined as > 1.0 cm in its longest dimension)

- Adequate hematological function: ANC 1000/mm3 or more, platelets 75,000/mm3 or more, hemoglobin 9 g/dL or more.
Transfusion and/or growth factor are allowed but counts must be stable for at least 72 hours afterwards prior to screening

- Adequate liver function: total bilirubin <1.5x ULN, AST/ALT 3xULN or less
Note: Patients with documented history of Gilbert's Syndrome and in whom total bilirubin elevations are accompanied by elevated indirect bilirubin are eligible

- Adequate renal function: creatinine clearance (CrCl) of 45 mL/min or more

- Diagnosis of CLL, Burkitt lymphoma, or Richter's transformation

- Active CNS involvement by B-NHL

- Leukemic presentation of B-NHL

- History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

- Prior therapy with T-cell engager (TCE) within 8 weeks, CAR T- cell therapy or autologous

- Hematopoietic Stem Cell Transplantation (HSCT) within 12 weeks, or prior allogeneic HSCT within 24 weeks of first dose of AZD0486

- Requires chronic immunosuppressive therapy

- Unresolved non hematological AEs Grade 2 or more from prior therapies; history of Grade 3 or more CRS or neurotoxicity from prior CAR-T or TCE therapy

- History of major cardiac abnormalities.

- If female, participant must not be pregnant or breastfeeding.

Both

B-cell Non-Hodgkin Lymphoma
- Follicular Lymphoma (FL)
- Diffuse Large B-Cell Lymphoma (DLBCL)

- Module 1: AZD0486 Monotherapy in Participants with Relapsed or Refractory Follicular Lymphoma
Drug: AZD0486
Investigational Product administered via intravenous infusion.

- Module 2: AZD0486 Monotherapy in Participants with Relapsed or Refractory DLBCL
Drug: AZD0486
Investigational Product administered via intravenous infusion.

ORR, defined as the proportion of participants achieving either a PR or CR based on Lugano 2014 Response Criteria as determined by an IRC

+81-96-353-6501

Oct. 10, 2024

Yes

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Canada/United States/Brazil/United Kingdom/Spain/France/Italy/Denmark/Germany/Australia/Sweden/South Korea/Taiwan/China/Hong Kong